The Material Difference: FDA Warning Letters Reinforce 510(k) Expectations for Material Changes November 11, 2026 By Adrienne R. Lenz, Principal Medical Device Regulation Expert —

https://www.thefdalawblog.com/2026/11/the-material-difference-fda-warning-letters-reinforce-510k-expectations-for-material-changes/?utm_source=rss&utm_medium=rss&utm_campaign=the-material-difference-fda-warning-letters-reinforce-510k-expectations-for-material-changes FDA’s guidance Deciding When to Submit a 510(k) for a Change to an Existing Device provides recommendations for evaluating changes to devices to determine when a new 510(k) should be submitted. For a change to a device’s patient-contacting materials, the guidance frames the significance analysis around whether a risk assessment identifies any new or increased biocompatibility concerns. If so, the change is generally considered significant and a new 510(k) should be submitted. Discussion related to this question states that an example of a new concern would be “a material change that requires a new type of biocompatibility test, such as an implantation test, that was not required for the original device” or “where a new chemical component added to a material requires a genotoxicity analysis of the component (because, for instance, the particular component is noted in the literature as potentially genotoxic), but the original device already required a genotoxicity analysis.”